Urologic Health Inc., a medical device company pioneering non-invasive urodynamics, today announced the successful closing of an $11 million seed financing round led by an undisclosed strategic ...
Trial shows promise: enGene’s gene therapy for high-risk, BCG-unresponsive bladder cancer achieved a 54% complete response rate, with low progression to advanced disease. Device gains clearance: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results